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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.019PTEN and PIK3CA mutations occur with high frequency in uterine endometrioid carcinoma (UEC).
Although PTEN mutations are present in complex atypical hyperplasia and carcinoma, PIK3CA mutations
are restricted to carcinoma. We generated mouse models harboring Pten loss and/or activated Pik3ca in
the endometrial epithelium to investigate their respective roles in the pathogenesis of UEC. Presence of
an activated mutant Pik3ca on the background of Pten loss led to aggressive disease, with 100% of mice
exhibiting carcinoma. Expression of Pik3ca with E545K mutation alone was unable to cause hyperplasia
or cancer in the uterus and did not activate Akt as effectively as Pten deletion in short-term cultures of
mouse endometrial epithelium, likely explaining the lack of phenotype in vivo. We also report that
nuclear localization of FOXO1 correlated with PTEN mutational status irrespective of the PIK3CA status
in endometrial cancer cell lines. Furthermore, gene expression proﬁles resulting from Pten loss or
activation of Pik3ca in primary mouse endometrial epithelial cells exhibit minimal overlap. Thus,
Pten and Pik3ca have distinct consequences on the activation of the phosphatidylinositol 3-kinase
pathway in endometrial epithelium and are likely to affect other nonoverlapping cellular mechanisms
involved in the development and progression of the most common type of uterine cancer. (Am J Pathol
2015, 185: 1104e1113; http://dx.doi.org/10.1016/j.ajpath.2014.12.019)Supported by NIH/National Cancer Institute grants RO1 CA188516
(S.J.B.) and R01 CA095427 (L.H.E).
Disclosures: None declared.Endometrial carcinoma is a signiﬁcant cause of morbidity
and mortality worldwide, and in the United States, it is the
eighth most common cause of cancer-related deaths in
women.1 Endometrial carcinoma is most often of endome-
trioid morphology, and is usually preceded by complex
atypical hyperplasia (CAH). The development of both
endometrial hyperplasia and uterine endometrioid carci-
noma (UEC) is associated with unopposed estrogen stimu-
lation and/or speciﬁc genetic alterations.1 Approximately
30% to 80% of primary UECs harbor PTEN mutations,2e4
with a similar frequency detected in CAH. In contrast,
PIK3CA mutations occur in 20% to 40% of UECs and are
rarely, if ever, found in CAH.
Phosphatase and tensin homolog (PTEN) and PIK3CA
are main components of the phosphatidylinositol 3-kinase
(PI3K)/AKT/PTEN pathway with opposing actions.
PIK3CA encodes the p110a catalytic subunit of the PI3K
complex and is considered an oncogene. As a component ofstigative Pathology.
.PI3K, it is activated downstream of growth factor signaling,
resulting in phosphorylation of phosphatidylinositol-4,5-
phosphate (PIP2) to generate phosphatidlyinositol-3,4,5-
phosphate (PIP3). PIP3 activates AKT, a protein kinase
that regulates several downstream pathways that impinge on
cell proliferation, cell growth, and apoptosis. In contrast,
PTEN is a tumor-suppressor gene encoding a dual-
speciﬁcity phosphatase, capable of dephosphorylating both
proteins and lipids. Its most well-described activity is the
conversion of PIP3 to PIP2, indirectly inhibiting the action
of PI3K. Thus, by preventing AKT activation, PTEN in-
hibits cell proliferation.5,6
Most PTEN mutations in CAH and UEC are localized to
exons encoding the lipid phosphatase domain, resulting in
Pten and Pik3ca in Endometrial Carcinomaloss of its ability to dephosphorylate PIP3.2,7,8 PIK3CA
mutations, E542K E545K (both in exon 9) and H1047R (in
exon 20), are hotspots, found in endometrial carcinoma, as
well as several other cancers and lead to constitutive acti-
vation of p110a.5 Because loss of PTEN or activation of
PIK3CA lead to activation of the pathway, it is reasonable to
assume that they have similar downstream effects. However,
as noted above, PTEN mutations are found in both CAH and
UEC, whereas PIK3CA mutations are almost exclusively
found in UEC, suggesting unique and nonoverlapping
functions in endometrial carcinoma pathogenesis.
Ptenþ/ female mice develop CAH by 32 weeks of age,
and at approximately 52 weeks of age, 25% of the Ptenþ/
female mice develop UEC. Both CAH and UEC exhibit
complete loss of Pten expression, as a result of biallelic Pten
inactivation by either loss of heterozygosity or intragenic
mutations in the wild-type allele.9,10 In this mouse model,
the frequency of biallelic inactivation is similar in CAH and
UEC, and we have previously shown that mismatch repair
deﬁciency hastens inactivation of the remaining Pten allele
and promotes the progression of hyperplastic lesions to
UEC.9 These observations suggest that, although biallelic
inactivation of Pten is an early event in endometrial
tumorigenesis, it may not be sufﬁcient for progression to
invasive carcinoma. Given the genetic analyses of primary
human tumors, it seems likely that mutations in PIK3CA
may promote progression to carcinoma.
To determine the effect of loss of PTEN and/or activated
PIK3CA in the development of UEC, we have developed
several genetic mouse models. The results reported herein
demonstrate distinct roles of these two genes in the patho-
genesis of endometrial carcinoma.
Materials and Methods
Animals
PtenloxP/loxP mice on a Balbc/129SvJ background and
Ksp1.3-Creþ/ mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME). To investigate the role of Pik3ca, a
mouse line with a Cre-inducible mutant form of Pik3ca
(designated as Pik3caE545K/þ) was constructed in the labo-
ratory of Dr. Suzanne Baker (St. Jude Children’s Research
Hospital, Memphis, TN). The Pik3caE545K/þ mouse contains
a lox-STOP-lox cassette upstream of the Pik3ca gene con-
taining the E545K mutation. In the presence of Cre, the stop
codon is excised such that the mutant allele is expressed from
its endogenous promoter. These mice were bred with
PtenloxP/loxP strain to generate PtenloxP/loxP;Pik3caE545K/þ
(Ptenf/f;Pik3caE545K), PtenloxP/loxP;Pik3caþ/þ (Ptenf/f), Ptenþ/þ;
Pik3caE545K/þ (Pik3caE545K), and PtenloxP/þ;Pik3caE545K/þ
(Ptenf/þ;Pik3caE545K) mice. Mice expressing Cre under the
Wnt7a promoter (Wnt7a-Creþ/) were obtained from
Dr. Kenneth S. Korach (National Institute of Environmental
Health Science, Research Triangle Park, NC). Ptenf/f;
Pik3caE545K mice were crossed with the Wnt7a-Cre andThe American Journal of Pathology - ajp.amjpathol.orgKsp1.3-Cre mice to generate the described genotypes. All
animal experiments were performed in accordance with
Institutional Animal Care and Use Committee guidelines.
IHC Staining
The uteri harvested from all mice at indicated time points
were ﬁxed in formalin and embedded in parafﬁn. Sections
(5 mm thick) were processed for hematoxylin and eosin
staining and immunohistochemical (IHC) analysis. For IHC,
the slides were deparafﬁnized, rehydrated, and subjected to
antigen retrieval by boiling in the microwave in 10 mmol/L
sodium citrate. The Vectastain ABC reagent (Vector Labs,
Burlingame, CA) was then used according to the manu-
facturer’s protocol. Antibodies used were Pten (1:100),
phospho-Akt S473 (1:100), b-catenin (1:800), p-Gsk3b
(1:50), p-Pras40 (1:800), Stathmin (1:50), and FoxO1
(1:100), all from Cell Signaling Technologies (Beverly,
MA). Two human tissue microarrays (TMAs), one con-
taining 100 cases of normal cycling endometrium and the
second with 96 cases of UEC (24 International Federation of
Gynecology and Obstetrics grade 1, 37 International
Federation of Gynecology and Obstetrics grade 2, and 35
International Federation of Gynecology and Obstetrics
grade 3 cases) generated at Weill Cornell Medical College
(New York, NY) under Institutional Review Board approval
were also stained with FOXO1 antibody, as per the protocol
described above.
Microdissection
Areas corresponding to CAH, UEC, or normal epithelium
were microdissected from deparafﬁnized, rehydrated,
hematoxylin-stained sections (5 mm thick) under light mi-
croscope visualization with a 26-gauge needle. The DNA
was extracted using previously published protocols.11,12
Primary Uterine Epithelial Cell Cultures
Epithelial cells from uteri of Ptenf/f;Pik3caE545K, Ptenf/f, and
Pik3caE545K mice were prepared as described previously.13
Brieﬂy, the horns were slit lengthwise and digested in a
solution containing 0.25% trypsin in Hanks’ balanced salt
solution for 1 hour at 4C, followed by another incubation
for 1 hour at 22C. The tissue pieces were transferred to ice-
cold Hanks’ balanced salt solution and vortex mixed to
release sheets of epithelial cells. The cell suspension was
ﬁltered through a 20 mm nylon mesh, and the epithelial
sheets (retained on the ﬁlter) were collected and resus-
pended in Dulbecco’s modiﬁed Eagle’s medium/F12 (1:1),
10% charcoal-stripped fetal bovine serum, 20 mmol/L
HEPES, 100 mg/mL streptomycin, 100 U/mL penicillin, and
2 mmol/L L-glutamine and insulin-transferrin-selenium
supplement (1). Cells were plated in 6-well dishes coated
with 1:10 diluted Matrigel (Life Technologies, Grand
Island, NY) and cultured at 37C in an incubator with 5%1105
Joshi et alCO2. After reaching 80% to 90% conﬂuence, the cells were
infected with adenoviruses expressing Cre or green ﬂuo-
rescent protein (GFP; control), as described previously,13
for 48 hours. Cells were harvested for RNA or protein
extraction. The RNA was used for RNA sequencing analysis
and for subsequent validation of differentially expressed
genes (DEGs) by real-time quantitative PCR (qPCR). Whole
cell protein lysates were used for immunoblot analysis using
Pten, phospho-Akt, and Akt antibodies (Cell Signaling
Technologies), all at 1:1000 dilution. Actin antibody (Sigma,
St. Louis, MO) was used for normalization.
Nuclear and Cytoplasmic Extract Preparation
Endometrial cancer cell lines Hec1A parental clone (Hec1A
WT) and PTEN-deleted Hec1A (Hec1A clone 16) have been
described previously.14 KLE and RL95 cells were purchased
from ATCC (Manassas, VA) and were cultured as per the
ATCC protocol. Nuclear and cytoplasmic extracts were pre-
pared using the NE-PER Nuclear Protein Extraction Kit from
Thermo Fisher Scientiﬁc (Waltham, MA), as per the manu-
facturer’s protocol. The extracts were resolved by 4% to 20%
SDS-PAGE and transferred to a polyvinylidene diﬂuoride
membrane, and immunoblot analysis was performed using
p-FOXO1 and FOXO1 antibodies. Lamin A/C and glycer-
aldehyde-3-phosphate dehydrogenase antibodies were used to
ensure purity of the nuclear and cytoplasmic extracts,
respectively. All antibodies were purchased from Cell
Signaling Technologies and used at a dilution of 1:1000.
RNA Sequencing and Analysis
Total RNA was extracted from the cells using the RNeasy
Plus Universal Micro kit (Qiagen, Valencia, CA), as per the
manufacturer’s instructions. After isolation, total RNA
integrity was checked using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA), and samples with RNA
integrity number value greater than eight were used for li-
brary preparation and sequencing. Library construction,
template hybridization, and cluster ampliﬁcation were per-
formed using the TruSeq RNA Sample Preparation Kit
version 2 (Illumina Inc., San Diego, CA). After cluster
generation, sequencing by synthesis was performed on the
HiSeq2000/1000 machine (Illumina Inc.).
The RNA sequencing data were analyzed using Genesifter
software (Geospiza, Seattle, WA). Raw reads from an Illu-
mina HiSeq2000 in fastq format were ﬁltered to remove any
reads that contained primarily adaptor/primer sequences.
Reads were then aligned using Burrows-Wheeler Aligner
against the genomic reference sequence for Mus musculus
(Build 37.2). The Mus musculus (Build 37.2) reference
sequence and annotation were pulled from RefSeq
database (http://www.ncbi.nlm.nih.gov/refseq; last accessed
November 12, 2014), and reads mapping to the genome were
characterized as exon, intron, or intergenic (outside any an-
notated gene). These aligned data were then used to calculate1106gene expression by taking the total of exon and known splice
reads for each annotated gene to generate a count value per
gene. For each gene, a normalized expression value was
generated in two ways: reads per mapped million (RPMM;
which is calculated by taking the count value and dividing it
by the number of million mapped reads) and RPMM per
kilobase (RPMM value divided by the kilobase length of the
longest transcript for each gene). The RPMM values were
used for comparing gene expression across samples to
remove the bias of different numbers of reads mapped per
sample. RPMM per kilobase values were used for comparing
relative expression of genes to one another to remove the bias
of different numbers of mapped reads and different transcript
lengths. Samples were initially analyzed in a pairwise fashion
with normalization by the number of million mapped reads
(not including rRNA, tRNA, snRNA, or mitochondrial
RNA), followed by likelihood ratio test, and Benjamini and
Hochberg correction testing for signiﬁcance via Bio-
conductor. After the statistical qualiﬁcation of expression
values, the data were ﬁltered for genes that were threefold
differentially expressed. A multiple sample analysis was also
performed wherein GFP-treated (control) cells were
compared to Cre-treated cells from Ptenf/f;Pik3caE545K, Ptenf/f,
and Pik3caE545K genotypes. For this analysis, the data were
ﬁltered for genes that were also threefold differentially regu-
lated, and a Kyoto Encyclopedia of Genes and Genomes
pathway analysis was performed. We initially focused on
genes in the endometrial cancer and Wnt signaling pathways.
qPCR Validation of DEGs
Validation of DEGs was done by qPCR. We ﬁrst used cDNA
prepared from the same RNA used for RNA sequencing as
technical validation. For biological validation, RNA was
extracted from adenovirus-Creetreated primary cultures of
epithelial cells from at least two independent experiments, as
described inMaterials andMethods. RNA (1.0 mg) was reverse
transcribed using the High Capacity RNA-to-cDNA Kit (Life
Technologies), as per the manufacturer’s instructions. Volume
of reverse transcriptase reaction corresponding to 25 ng cDNA
was used to set up qPCRs using TaqMan primer-probe sets
from Life Technologies in the StepOnePlus PCR machine, and
fold differences in gene expression were calculated using the
DDCT method.
Results
Pik3caE545K/þ Mutation Causes Carcinoma in the
Setting of Biallelic Pten Deletion
The epithelium-restricted expression levels of theWnt7a15 and
Ksp1.316e18 promoters in the endometrium have been
described previously. Therefore, Ptenf/f;Pik3caE545K mice were
crossed with two mouse strains expressing Cre under Wnt7a
(Wnt-Cre) or Ksp1.3 (Ksp-Cre) promoters to delete Pten or
express mutant activated Pik3ca in the uterine epithelium.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Photomicrographs of hematoxylin and eosin (H&E)estained
mouse uteri. A and B: Complex atypical hyperplasia (CAH; A) and hemorrhagic
cysts (B) in Wnt-Creþ/;Ptenf/þ;Pik3caE545K uteri at 5 months of age. C: Low-
magniﬁcation H&E image of Ksp-Creþ/;Ptenf/f mice with CAH involving
entire luminal and glandular epithelium. D: High-magniﬁcation image of CAH
with areas of squamous metaplasia. E and F: Low-magniﬁcation (E) and high-
magniﬁcation (F) image of Ksp-Creþ/;Ptenf/f;Pik3caE545K uteri with carcinoma
and myometrial invasion. G: Gross morphological features of Ksp-Creþ/;
Ptenf/f;Pik3caE545K uteri with both ovaries engulfed in cysts. H: Gross
morphological features of Ksp-Creþ/;Ptenf/f mice exhibiting uterine disease
but normal ovaries. I: Low-magniﬁcation H&E image of Ksp-Creþ/;Pik3caE545K
uterus with normal histological features. J: High-magniﬁcation image of I.
Original magniﬁcations: 200 (A, D, F, and J); 40 (B, C, E, and I).
Pten and Pik3ca in Endometrial CarcinomaUteri of Wnt-Creþ/;Ptenf/þ;Pik3caE545K, Wnt-Creþ/;
Ptenf/þ, and Wnt-Creþ/;Pik3caE545K mice were analyzed at
5 months of age. This time point was determined due to the
development of lymphoma and breast cancers in many of
the Wnt-Creþ/;Ptenf/þ;Pik3caE545K mice at this age. The
Wnt-Cre and Ptenf/f;Pik3caE545K crosses never produced
Wnt-Creþ/;Ptenf/f;Pik3caE545K or Wnt-Creþ/;Ptenf/f mice,
likely due to embryonic expression of Wnt7a with subse-
quent lethality. Ten of 15 Wnt7a-Creþ/;Ptenf/þ;
Pik3caE545K and 12 of 17 Wnt-Creþ/;Ptenf/þ female mice
developed CAH (Figure 1A and Table 1). Only two Wnt-
Creþ/;Ptenf/þ;Pik3caE545K mice exhibited in situ carcinoma
and/or myoinvasive carcinoma. We did not observe signiﬁ-
cant differences between the number of CAH foci and
severity of disease between Wnt-Creþ/;Ptenf/þ and Wnt7a-
Creþ/;Ptenf/þ;Pik3caE545K genotypes. Interestingly, uteri of
Wnt-Creþ/;Ptenf/þ;Pik3caE545K mice exhibited lymphatic
dilation and hemorrhagic cysts (Figure 1B). Of 15 Wnt7a-
Creþ/;Ptenf/þ;Pik3caE545K mice, 9 also developed
lymphoma and breast lesions, likely due to expression of
Wnt-Cre in these tissues. None of the 17 Wnt-Creþ/;Ptenf/þ
mice developed hemorrhagic cysts, lymphomas, or breast
lesions. All Wnt-Creþ/;Pik3caE545K mice (nZ 7) exhibited
normal uterine histological features at 5 months of age and
also lacked hemorrhagic cysts, lymphoma, and breast lesions.
Mating of Ptenf/f;Pik3caE545K and Ksp1.3-Cre mouse
strains generated Ksp-Creþ/;Ptenf/þ;Pik3caE545K, Ksp-Creþ/;
Ptenf/þ, Ksp-Creþ/;Ptenf/f, Ksp-Creþ/;Ptenf/f;Pik3caE545K,
and Ksp-Creþ/;Pik3caE545K/þ genotypes. Previously pub-
lished work from our laboratory demonstrated that Ptenf/f
mice injected with adeno-Cre virus developed carcinoma
between 2 and 4 months after injection.13 We, therefore,
chose to sacriﬁce mice of the ﬁve genotypes mentioned
above at 4 months of age (Table 2). Eleven of 12 Ksp-
Creþ/;Ptenf/þ;Pik3caE545K and 12 of 16 Ksp-Creþ/;
Ptenf/þ mice exhibited CAH only. The number of foci of
CAH was comparable in Ksp-Creþ/;Ptenf/þ;Pik3caE545K
and Ksp-Creþ/;Ptenf/þ genotypes, to those observed in the
Wnt7a-Creþ/;Ptenf/þ;Pik3caE545K mice and the Wnt-Creþ/;
Ptenf/þ mice. However, in the Wnt7a-Creþ/;Ptenf/þ;
Pik3caE545K genotype, two mice developed invasive carci-
nomas that were not observed in the Ksp-Creþ/;Ptenf/þ;
Pik3caE545K mice. All Ksp-Creþ/;Ptenf/f mice (n Z 8)
developed extensive endometrial disease, with CAH involving
the entire luminal and glandular epithelium (Figure 1C). In
ﬁve of eight mice, CAH exhibited squamous metaplasia
(Figure 1D). Only one mouse (12%) showed carcinoma with
myometrial invasion. Hematoxylin and eosin analysis of Ksp-
Creþ/;Ptenf/f;Pik3caE545K uteri (n Z 6) showed CAH with
squamous metaplasia and carcinoma with myometrial invasion
(Figure 1, E and F) in all of the mice. In ﬁve mice, the gross
examination of the uterus demonstrated enlarged uteri with
ovaries engulfed by cysts that could not be distinguished from
the oviduct (Figure 1G) as compared to Ksp-Creþ/;Ptenf/f
mice (Figure 1H). The carcinoma was well to moderately
differentiated and extended into and completely surrounded theThe American Journal of Pathology - ajp.amjpathol.org 1107
Table 1 Endometrial Lesions in Wnt-Creþ/;Ptenf/þ;Pik3caE545K Mice and Littermates
Genotype
No. of
mice
Mice with endometrial
pathological features
Mice with
CAH
Average No.
of CAH foci
Mice with
CA/Inv
Breast/lymph node
pathological features
Wnt-Creþ/;Ptenf/þ;Pik3caE545K 15 10 8 6e7 2 9
Wnt-Creþ/;Ptenf/þ 17 12 12 7e8 0 0
Wnt-Creþ/;Pik3caE545K 7 0 0 0 0 0
CA, carcinoma; CAH, complex atypical hyperplasia; Inv, invasion.
Joshi et alovaries (Figure 1G). Thus, the presence of a mutant Pik3ca on
the background of biallelic Pten deletion resulted in extensive
invasive carcinoma with 100% penetrance. None of the Ksp-
Creþ/;Pik3caE545K mice developed endometrial disease
(Figure 1, I and J), similar to Wnt-Creþ/;Pik3caE545K mice.
Expression of Pik3caE545K Does Not Cause Endometrial
Carcinoma and Is Less Efﬁcient at Activating Akt in
Epithelial Cells
Carcinoma and/or CAH did not develop in mice regardless of
the promoter used to activate Pik3ca. This lack of phenotype
could be due to inefﬁcient DNA recombination of the mutant
Pik3ca allele or lack of clonal selection in endometrial
epithelial cells expressing mutant Pik3ca. To determine the
reason, we used PCR analysis to ascertain excision of the
STOP codon upstream of exon 1 in the Pik3ca mutant allele
by Cre recombinase. Presence of a recombined allele leads to
ampliﬁcation of a 735-bp band, whereas the nonrecombined
allele ampliﬁes a 637-bp band. Areas of CAH and carcinoma
were microdissected from tissue sections of Ksp-Creþ/;
Ptenf/f;Pik3caE545K, Ksp-Creþ/;Ptenf/f, and Ksp-Creþ/;
Ptenf/þ;Pik3caE545K uteri. DNA was extracted and analyzed
by PCR. DNA from Ksp-Creþ/;Ptenf/f;Pik3caE545K and
Ksp-Creþ/;Ptenf/þ;Pik3caE545K uteri ampliﬁed both 637-
and 735-bp bands (Figure 2A), proving that the mutant allele
had undergone recombination in the lesions from these mice.
DNA extracted from Ksp-Creþ/;Ptenf/f uteri ampliﬁed only
a 637-bp band, as expected (Figure 2A). DNA was also
extracted from normal epithelium of Ksp-Creþ/;
Pik3caE545K mice and PCR ampliﬁed a 637-bp non-
recombined band, but a faint 735-bp band from the
recombined allele was detected (Figure 2A). This obser-
vation suggested that even though recombination
occurred, epithelial cells with the recombined allele do
not have a signiﬁcant growth advantage in this setting.Table 2 Endometrial Lesions in Ksp-Creþ/-;Ptenf/f;Pik3caE545K Mice and
Genotype
No. of
mice
Mice with endom
pathological fea
Ksp-Creþ/;Ptenf/þ;Pik3caE545K 12 11
Ksp-Creþ/;Ptenf/þ 16 12
Ksp-Creþ/;Pik3caE545K 6 0
Ksp-Creþ/;Ptenf/f 8 8
Ksp-Creþ/;Ptenf/f;Pik3caE545K 6 6
CA, carcinoma; CAH, complex atypical hyperplasia; Inv, invasion.
1108We also performed IHC analysis on the tissue sections
using p-Akt antibody. Although areas of CAH and carci-
noma in all of the genotypes with endometrial pathological
features (Figure 2B) exhibited characteristic membrane
staining for p-Akt, the epithelium or glands in Ksp-Creþ/;
Pik3caE545K mice (Figure 2C) were completely negative for
p-Akt. The uteri of Wnt-Creþ/;Pik3caE545K mice were also
negative for p-Akt staining (data not shown).
Pik3ca was activated in vitro by adeno-Cre treatment of
primary epithelial cells isolated from Ptenf/f and Ptenf/f;
Pik3caE545K mice. Adeno-GFPetreated cells were used as
control cells (GFP). We have previously demonstrated that
in vitro adeno-Creemediated Pten deletion in epithelial
cells results in activation of Akt.13 In cells prepared from
Pik3caE545K mice, Akt was activated but was severalfold
lower than that observed in Ptenf/f or Ptenf/f;Pik3caE545K
cells (Figure 2D). Thus, mutant Pik3ca alone results in a
much less robust activation of Akt, compared to loss of
Pten, in endometrial epithelial cells. Quantitation of the
immunoblot analysis is depicted in Figure 2E.
Expression of Downstream Signaling Molecules in the
PI3K/Pten/Akt Pathway
Next, we performed IHC analysis on uterine sections fromKsp-
Creþ/;Ptenf/þ, Ksp-Creþ/;Ptenf/þ;Pik3caE545K, Ksp-Creþ/;
Ptenf/f, and Ksp-Creþ/;Ptenf/f;Pik3caE545K mice with anti-
bodies against p-Gsk3b, p-Pras40, Stathmin, and FoxO1,
which are known substrates of p-Akt. IHC analysis was also
performed using antibodies against b-catenin because
cytoplasmic and nuclear accumulation of b-catenin has
been associated with squamous metaplasia. In the geno-
types with CAH and carcinoma, the lesions expressed
p-Gsk3b and p-Pras40 (Figure 3, A and B), whereas normal
epithelium was negative (Figure 3, A and B), correlating
with activation of the pathway. Stathmin and b-cateninLittermates
etrial
tures
Mice with
CAH
Average No.
of CAH foci
Mice with
CA/Inv
11 8 0
12 9e10 0
0 0 0
8 Extensive 1
6 Extensive 6
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Figure 3 Immunohistochemical (IHC) analysis of downstream signaling
molecules. A and B: Positive IHC staining with p-Gsk3b (A) and p-Pras40
(B) antibodies in uteri with complex atypical hyperplasia (CAH; arrow) as
compared to normal epithelium (arrowheads). C: Loss of nuclear FoxO1
staining in CAH (arrows) compared to the intense nuclear staining of
normal epithelium (arrowheads). D: Loss of nuclear FoxO1 in carcinoma. E:
Immunoblot analysis depicting subcellular localization of FOXO1 in endo-
metrial cancer cell lines. Lamin A/C and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) served as controls to determine relative purity of
nuclear (N) and cytoplasmic (C) extracts. WT, wild type.
Figure 2 Recombination of mutant Pik3ca allele and activation of Akt
in primary cultures. A: Agarose gel electrophoresis of PCR analysis of DNA
extracted from microdissected, formalin-ﬁxed, parafﬁn-embedded tissue
from Ksp-Creþ/;Pik3caE545K (lane 1), Ksp-Creþ/;Ptenf/þ;Pik3caE545K (lane
2), Ksp-Creþ/;Ptenf/f (lane 3), and Ksp-Creþ/;Ptenf/f;Pik3caE545K (lane 4)
mice. B and C: p-Akt immunohistochemical analysis of uterine sections of
Ksp-Creþ/;Ptenf/þ;Pik3caE545K (B) and Ksp-Creþ/;Pik3caE545K (C) mice. D:
Immunoblot analysis of whole cell extracts of Adeno-GFP or Adeno-Cree
treated primary uterine epithelial cells isolated from Ptenf/f, Pik3caE545K,
and Ptenf/f;Pik3caE545K mice using Pten, p-Akt, Akt, and actin antibodies. E:
Quantitation of p-Akt in D. Graph represents p-Akt/Akt ratios from three
independent experiments. Data represent means  SD. GFP, green ﬂuo-
rescent protein; WB, water blank.
Pten and Pik3ca in Endometrial Carcinomaexpression was not altered, and b-catenin was localized to
cell membranes in normal and neoplastic cells, even in
areas of squamous metaplasia (Supplemental Figure S1).
FoxO1 expression was also signiﬁcantly altered. FoxO1
localization was nuclear in normal epithelium and stromal
cells (Figure 3C), but areas of CAH (Figure 3C) and car-
cinoma (Figure 3D) exhibited complete lack of nuclear
FoxO1 with reduced cytoplasmic expression, irrespective
of the genotypes. Pras40, Gsk3b, and FoxO1, therefore, are
likely downstream targets of Pten inactivation in the uterine
epithelium. IHC analysis with FOXO1 antibody was also
performed on TMAs of human endometrial carcinomas and
normal cycling (proliferative and secretory) endometria.
Intense nuclear expression was observed only in the normal
secretory epithelium but was absent in normal proliferative
epithelium, as reported previously.19 In contrast, 72% of
carcinomas (69 of 96 cases) lacked nuclear FOXO1The American Journal of Pathology - ajp.amjpathol.orgexpression. More important, the results with the human
TMA (Supplemental Table S1) corroborate the results
found in our genetic mouse model.
To further investigate lack of nuclear FOXO1, we
analyzed several endometrial cancer cell lines for subcellular
distribution and phosphorylation status of FOXO1 by
immunoblot analysis. Nuclear and cytoplasmic extracts were
prepared from KLE, RL95, Hec1A WT, and Hec1A clone16
(isogenic clone with somatic deletion of PTEN) cell lines
with unique combinations of mutations (Supplemental Table
S2) in PTEN and PIK3CA. FOXO1 was detected in both the
cytoplasm and the nucleus in Hec1A WT and KLE cells
(Figure 3E). In contrast, the Hec1A clone 16 and RL95
(mutated for PTEN) cell lines lacked nuclear FOXO1
expression and demonstrated reduced cytoplasmic expres-
sion. This observation correlates with the mouse studies1109
Figure 4 RNA sequencing analysis. A: Venn diagram depicting the
differentially expressed genes (DEGs) common and/or unique to Ptenf/f,
Pik3caE545K, and Ptenf/f;Pik3caE545K. B: Real-time quantitative PCR analysis
to validate expression of DEGs identiﬁed by RNA sequencing. Graph depicts
fold change in expression of Axin2, Hspa1a, and Cdkn2a in Ptenf/f,
Pik3caE545K, and Ptenf/f;Pik3caE545K cells as compared to green ﬂuorescent
protein (GFP)etreated cells. Means  SEM are summarized. NZ number of
independent experiments performed for each gene.
Joshi et aldescribed above and provides evidence that nuclear locali-
zation of FOXO1 is dependent on PTEN. In all of the cell
lines, p-FOXO1 was detected maximally in the cytoplasmic
compartment. The Hec1A cell lines (parent and clone) have a
G1049R mutation in PIK3CA yet fail to activate AKT
(Hec1AWT) in the absence of PTENdeletion (Hec1A clone).
Pten and Pik3ca Regulate Nonoverlapping Gene Sets
To delineate downstream changes in gene expression due to
deletion of Pten, activation of Pik3ca, or both, we performed
RNA sequencing analysis with RNA extracted from adeno-
Creetreated primary epithelial cell cultures prepared from
Ptenf/f, Pik3caE545K, and Ptenf/f;Pik3caE545K mice. Deletion
of Pten and expression of Pik3caE545K allele were conﬁrmed
at the RNA level by qPCR analysis (Supplemental Figure S2)
and were submitted for RNA sequencing analysis.1110A pairwise analysis was performed to individually
compare control (GFP) with Ptenf/f, Pik3caE545K, and Ptenf/f;
Pik3caE545K cells by setting a P cutoff at 0.05 and threefold
differential expression. Only four genes were altered in all
three conditions (Figure 4A). There was also minimal
overlap between Ptenf/f versus Pik3caE545K and Pik3caE545K
versus Ptenf/f;Pik3caE545K cells. Most of the DEGs were
unique to each condition (Supplemental Tables S3eS5).
This ﬁnding suggests that deletion of Pten and activation of
Pik3ca regulate distinct, nonoverlapping genes. For valida-
tion, we chose genes from the following groups: i) genes
regulated in all of the groups (Hspa1a), ii) genes regulated
in Pik3caE545K and Ptenf/f;Pik3caE545K cells (Cdkn2a), and
iii) genes regulated maximally in Ptenf/f cells (Axin 2).
Validation was performed on cDNA from total RNA
extracted from three independent cell preparations. Regu-
lation of the three genes was similar to that observed by
RNA sequencing (Figure 4B).Discussion
Although PTEN and PIK3CA mutations occur at high fre-
quencies in endometrial carcinoma, their respective roles in
the neoplastic process remain unclear. We have been spe-
ciﬁcally interested in deﬁning the consequences of these
genetic alterations in the development of endometrial car-
cinoma. With the use of genetic mouse models reported
herein, along with human tissue samples and cell lines, we
have begun to dissect the impact of these two common
genetic alterations on endometrial carcinogenesis.
We have shown that mouse strains with conditional dele-
tion of Pten, as has been previously shown,13,20 predictably
develop endometrial hyperplasia that can progress to carci-
noma. In contrast, the isolated activation of Pik3ca in the
endometrial epithelium does not cause any phenotypic light
microscopic changes. However, the activation of Pik3ca in
the presence of Pten loss not only accelerates the progression
to carcinoma, but leads to more extensive disease with
extension into the ovaries. Interestingly, Pik3ca activation
does not lead to the development of more extensive hyper-
plasia or carcinoma in the setting of Pten haploinsufﬁciency,
and the frequency of CAH in Pten-haploinsufﬁcient mice
with or without Pik3ca activation was similar to germline
Ptenþ/ mice9 of the same age. This suggests that the rate-
limiting step in the development of hyperplasia is the bial-
lelic loss of Pten in the epithelium. The current ﬁndings
corroborate the mutational analyses of primary human tu-
mors and provide deﬁnitive evidence for a role of Pten in the
development of hyperplasia, with Pik3ca driving the transi-
tion to invasion in the endometrial epithelium.
We present evidence from primary mouse cultures, as
well as human cancer cell lines, that the extent of Akt
phosphorylation differs between loss of Pten and activation
of Pik3ca. Exon 9 and 20 mutations in p110a are hotspots
common across all cancer types,21,22 and these mutationsajp.amjpathol.org - The American Journal of Pathology
Pten and Pik3ca in Endometrial Carcinomaare equally effective in phosphorylating AKT in breast23
and colorectal cancer24 cell lines as well as primary uro-
thelial cells.25 However, in NIH3T3 cells, the kinase domain
H1047R mutation was severalfold more potent than the
helical domain E545K mutation at phosphorylating Akt,
suggesting that the extent of pathway activation by these
mutations (as seen by Akt phosphorylation) is cell context
dependent.25 In our studies, the E545K mutation resulted in
a much less robust activation of Akt when compared to Pten
in primary mouse endometrial epithelial cells. In human
endometrial cancer cell lines as well, phosphorylated AKT
was detected only in the cell lines with PTEN mutations
(Figure 3E and Supplemental Table S2), despite the pres-
ence of a G1049R mutation in PIK3CA, as has been
demonstrated previously.26 In endometrial epithelial cells,
therefore, both helical or kinase domain mutations were
unable to overcome the inhibitory effects of PTEN, which
likely explains, at least in part, the lack of phenotype in mice
expressing only the activated Pik3ca allele. To our knowl-
edge, this is the ﬁrst report to provide mechanistic insights
into the respective roles of Pten and Pik3ca in the endo-
metrial epithelium in vivo. Recently, studies using mouse
models of prostate and breast cancer highlighted the
importance of p110b over p110a isoform, particularly in the
context of PTEN deﬁciency.27,28 It has also been suggested
that the PI3K isoform dependence is affected by mutations
in other genes.29 However, p110b inhibition alone in
endometrial cancer cell lines was ineffective at inducing
apoptosis, irrespective of the PTEN status.26
FoxO1, a tumor-suppressor protein, is a well-characterized
downstream target of Akt. Nuclear FoxO1 is a transcription
factor activating expression of cell cycle inhibitors like p27
and p21, while repressing cyclins D1 and D2.30 Activated
Akt (as a result of Pten loss) phosphorylates FoxO1, leading
to nuclear export, inhibiting its transcriptional activity and thus
promoting cell proliferation and blocking apoptosis.30 FOXO1
in humans and mice has been demonstrated to play a role in
decidualization of stromal cells in the endometrium,31e33 and
its expression in the endometrial epithelium varies with the
stage of the menstrual/estrus cycle.34 Although UEC cases
have been shown to express reduced FOXO1 as compared to
the normal cycling endometrium,19,35 there is a lack of evi-
dence suggesting a direct link between PTEN mutation/
inactivation and reduced expression. In our mouse models
with CAH and UEC, FoxO1 expression was strikingly absent
in the nucleus as compared to the normal epithelium, in
agreement with the human data. As mentioned previously in
Results, a TMA consisting of primary human tumors also
showed lack of nuclear FOXO1 in 72% of cases. However,
because activation of Pik3ca alone in the mouse uterus did not
lead to endometrial disease, we were unable to dissect out the
role of Pten and Pik3ca in regulating FoxO1 using mouse
models. The human endometrial cancer cell lines proved ideal
to investigate the link between FOXO1 and PTEN. Nuclear
localization of FOXO1 correlated with presence of wild-type
PTEN, irrespective of PIK3CA status in endometrial cancerThe American Journal of Pathology - ajp.amjpathol.orgcell lines. This was particularly evident in Hec1A WT and
Hec1A clone 16 cells, which harbor a mutation in PIK3CA but
differ from each other only with respect to the lack of PTEN in
clone 16. Furthermore, KLE and RL95 (wild-type and mutant
for PTEN, respectively) also exhibited similar localization of
FOXO1. These observations provide evidence for a direct link
between PTEN and FOXO1 in UEC. The lack of FOXO1
expression in most human UEC cases and its loss in hyper-
plasia and carcinoma in the mouse model suggest a central
role for this transcription factor in the pathogenesis of endo-
metrial carcinoma. Interestingly, FOXO1 expression was up-
regulated as a result of progestin treatment of immortalized
and transformed endometrial epithelial cells19,35,36 and is
thought to mediate the progestin inhibition of epithelial pro-
liferation. Regulating FOXO1 expressionmay be central to the
mechanism by which PTEN promotes endometrial hyperpla-
sia, most likely by inhibiting cell death rather than increasing
proliferation. This is consistent with previous studies from our
laboratory showing that CAH and UEC arising in the mouse
model have lower proliferative indices than proliferative
endometrium.14 miRNA-mediated repression has also been
implicated in the regulation of FOXO1 levels in the endo-
metrial epithelium,37,38 but its relationship to PTEN is
currently unknown.
In addition to being less potent than Pten in activating
Akt, Pik3ca also regulates transcription of a distinct set of
genes in vitro, as demonstrated by RNA sequencing analysis
of adeno-Creetreated primary endometrial epithelial cell
cultures. Furthermore, combined Pten deletion and Pik3ca
activation altered expression of an entirely different set of
genes as compared to Pten deletion or Pik3ca activation
alone. Along with their roles as key players in the PI3K/
AKT/PTEN pathway, Pten and Pik3ca may also individu-
ally participate in other cellular processes in the endometrial
epithelium, providing a possible explanation for the frequent
co-occurrence of mutations in primary human tumors.11,39
Although these cell culture experiments are short-term and
they may not recapitulate the complex genetic alterations
observed in human cancers, they provide unique insights
into immediate downstream effects of Pten deletion and/or
Pik3ca activation. RNA sequencing on cells isolated from
the lesions arising in different genotypes might more closely
reﬂect the situation in human carcinogenesis.
In summary, the data presented herein provide unique
insights into the respective roles of PTEN and PIK3CA in
endometrial carcinoma. The PI3K/AKT pathway can be
activated by many signals like estrogen or growth factors,
secreted in a cyclic fashion in the endometrial epithelium,
inducing proliferation and differentiation. The results pre-
sented above strongly support PTEN as the prominent
suppressor of growth signals and show that the loss of
PTEN removes the inhibition leading to hyperplasia and that
PIK3CA mutations promote a transition to carcinoma. The
mechanism underlying this transition may be related to
further activation of AKT and likely regulation of other
nonoverlapping downstream molecules. Currently, we are1111
Joshi et alpursuing the identiﬁcation and characterization of molecules
and pathways critical to the development of carcinoma.
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